WallStSmart

Boston Scientific Corp (BSX)vsEnbridge Inc (ENB)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Enbridge Inc generates 216% more annual revenue ($65.19B vs $20.61B). BSX leads profitability with a 17.3% profit margin vs 11.5%. BSX appears more attractively valued with a PEG of 0.68. BSX earns a higher WallStSmart Score of 71/100 (B).

BSX

Strong Buy

71

out of 100

Grade: B

Growth: 8.0Profit: 7.0Value: 5.3Quality: 5.5
Piotroski: 4/9

ENB

Buy

63

out of 100

Grade: C+

Growth: 7.3Profit: 6.5Value: 4.7Quality: 4.5
Piotroski: 3/9Altman Z: 0.61
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BSXSignificantly Overvalued (-22.6%)

Margin of Safety

-22.6%

Fair Value

$46.16

Current Price

$53.93

$7.77 premium

UndervaluedFair: $46.16Overvalued
ENBUndervalued (+4.6%)

Margin of Safety

+4.6%

Fair Value

$54.02

Current Price

$53.59

$0.43 discount

UndervaluedFair: $54.02Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BSX4 strengths · Avg: 8.8/10
EPS GrowthGrowth
100.0%10/10

Earnings expanding 100.0% YoY

Market CapQuality
$84.08B9/10

Large-cap with strong market position

PEG RatioValuation
0.688/10

Growing faster than its price suggests

Operating MarginProfitability
20.6%8/10

Strong operational efficiency at 20.6%

ENB4 strengths · Avg: 9.3/10
EPS GrowthGrowth
294.9%10/10

Earnings expanding 294.9% YoY

Debt/EquityHealth
0.1010/10

Conservative balance sheet, low leverage

Market CapQuality
$116.95B9/10

Large-cap with strong market position

Price/BookValuation
2.9x8/10

Reasonable price relative to book value

Areas to Watch

BSX0 concerns · Avg: 0/10

No major concerns identified

ENB4 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
5.732/10

Expensive relative to growth rate

Free Cash FlowQuality
$-97.00M2/10

Negative free cash flow — burning cash

Altman Z-ScoreHealth
0.612/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : BSX

The strongest argument for BSX centers on EPS Growth, Market Cap, PEG Ratio. Profitability is solid with margins at 17.3% and operating margin at 20.6%. Revenue growth of 11.6% demonstrates continued momentum.

Bull Case : ENB

The strongest argument for ENB centers on EPS Growth, Debt/Equity, Market Cap.

Bear Case : BSX

No major red flags identified for BSX, but monitor valuation.

Bear Case : ENB

The primary concerns for ENB are Piotroski F-Score, PEG Ratio, Free Cash Flow.

Key Dynamics to Monitor

BSX profiles as a mature stock while ENB is a value play — different risk/reward profiles.

ENB carries more volatility with a beta of 0.79 — expect wider price swings.

BSX is growing revenue faster at 11.6% — sustainability is the question.

BSX generates stronger free cash flow (171M), providing more financial flexibility.

Bottom Line

BSX scores higher overall (71/100 vs 63/100), backed by strong 17.3% margins and 11.6% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Boston Scientific Corp

HEALTHCARE · MEDICAL DEVICES · USA

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

Enbridge Inc

ENERGY · OIL & GAS MIDSTREAM · USA

Enbridge Inc. is an energy infrastructure company. The company is headquartered in Calgary, Canada.

Want to dig deeper into these stocks?